Is Ardent Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Ardent Health, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current price of 14.63, especially when compared to the broader market performance and its peers. Key valuation ratios are not available for direct comparison, but the lack of qualifying peers suggests a unique position within its industry. In terms of performance, Ardent Health has faced significant challenges, with a year-to-date return of -14.34% compared to the S&P 500's positive return of 13.30%. This stark contrast reinforces the notion that the stock may be overvalued, as it has underperformed the market substantially over the past year.